...
首页> 外文期刊>Cancer investigation >Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer
【24h】

Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer

机译:对诱导化疗的临床反应预测炎症乳腺癌组合式乳腺癌后的结果

获取原文
获取原文并翻译 | 示例

摘要

Purpose: To assess predictors of outcome in a cohort of Inflammatory Breast Cancer (IBC) patients receiving induction chemotherapy followed by local treatment. Methods: We retrospectively reviewed 95 non-metastatic IBC patient files. Results: Complete clinical response (cCR) was obtained in 15 (16%) patients. Median follow up was 13.4 years (IC95%: 10.4-14.6). Loco-regional control (LC), disease-free survival (DFS), and overall survival (OS) at 5 years were 85%, 41%, and 55%, respectively; cCR was associated with better DFS and OS in multivariate analyses adjusted for age (p = 0.02). Conclusions: Clinical response to upfront chemotherapy predicts the outcome of patients affected by IBC.
机译:目的:评估接受诱导化疗的炎症乳腺癌(IBC)患者队列的结果预测因子,然后进行局部治疗。 方法:回顾性地审查了95例非转移性IBC患者文件。 结果:15名(16%)患者中获得完整的临床反应(CCR)。 后续位于13.4岁(IC95%:10.4-14.6)。 10岁的基因核区域对照(LC),无病生存(DFS)和总生存率(OS)分别为85%,41%和55%; CCR与调整年龄的多变量分析中的更好的DFS和OS相关(P = 0.02)。 结论:对前期化疗的临床反应预测受IBC影响的患者的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号